Illumina, Inc. $ILMN Stock Bought by Bank Julius Baer & Co. Ltd Zurich

Illumina logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Bank Julius Baer & Co. Ltd Zurich increased its Illumina stake by 1,901% in the third quarter, adding 5,893 shares to hold 6,203 shares worth about $1.7 million. Institutional investors collectively own 89.42% of the company.
  • Illumina’s latest quarterly results beat estimates: EPS was $1.62 versus $1.36 expected, and revenue of $1.17 billion rose 4.2% year over year. The company was also selected to provide whole-genome sequencing for a Singapore study expected to include about 450,000 people, though no contract value was disclosed.
  • Shares were reported down 4.9%, while analyst views were mixed; the consensus rating was Hold with an average price target of $244.24. Insiders sold 1.32 million shares worth about $288 million over the prior three months.
  • Five stocks to consider instead of Illumina.

Bank Julius Baer & Co. Ltd Zurich lifted its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1,901.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,203 shares of the life sciences company's stock after acquiring an additional 5,893 shares during the period. Bank Julius Baer & Co. Ltd Zurich's holdings in Illumina were worth $1,697,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Illumina in the 2nd quarter valued at $3,374,423,000. Primecap Management Co. CA acquired a new stake in Illumina during the 2nd quarter worth $617,981,000. Jupiter Topco LLC acquired a new stake in Illumina during the 2nd quarter worth $358,652,000. WCM Investment Management LLC lifted its holdings in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Illumina during the second quarter worth about $293,846,000. Institutional investors own 89.42% of the company's stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

Insider Activity

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares of the company's stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the transaction, the director owned 770,350 shares of the company's stock, valued at approximately $168,244,440. This represents a 13.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,320,108 shares of company stock worth $288,195,392 over the last three months. Insiders own 2.90% of the company's stock.

Illumina Trading Down 4.9%

NASDAQ ILMN opened at $226.54 on Thursday. The stock has a market capitalization of $34.25 billion, a price-to-earnings ratio of 45.37, a PEG ratio of 3.23 and a beta of 1.46. The stock's 50 day moving average price is $249.77 and its two-hundred day moving average price is $177.46. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company had revenue of $1.17 billion during the quarter, compared to analysts' expectations of $1.15 billion. During the same period last year, the business earned $1.34 EPS. The business's quarterly revenue was up 4.2% on a year-over-year basis. As a group, analysts anticipate that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of research analyst reports. Weiss Ratings raised Illumina from a "hold (c)" rating to a "buy (b-)" rating in a research note on Monday. Stephens lowered Illumina from an "overweight" rating to an "equal weight" rating and set a $275.00 price target on the stock. in a research report on Friday, October 23rd. JPMorgan Chase & Co. dropped their price target on Illumina from $320.00 to $300.00 and set an "overweight" rating on the stock in a research report on Friday, October 30th. UBS Group upgraded Illumina from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $135.00 to $260.00 in a report on Wednesday, September 9th. Finally, Piper Sandler boosted their price objective on Illumina from $225.00 to $305.00 and gave the company an "overweight" rating in a research report on Monday, September 28th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $244.24.

View Our Latest Stock Report on Illumina

Illumina Profile

(Free Report)

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

Recommended Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Illumina Right Now?

Before you consider Illumina, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.

While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines